home / stock / axim / axim news

AXIM News and Press, Axim Biotechnologies Inc From 09/15/21

Stock Information
Company Name: Axim Biotechnologies Inc
Stock Symbol: AXIM
Market: OTC
Website: aximbiotech.com
Menu
AXIM AXIM Quote AXIM Short AXIM News AXIM Articles AXIM Message Board
Get AXIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AXIM - AXIM® Biotech Appoints Ophthalmic Industry Veteran Jeff Busby as Senior VP Business Development

SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for COVID-19, dry eye disease (DED) and Cancer, today ann...
AXIM - AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files Amended Emergency Use Authorization with FDA for its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations

SAN DIEGO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease di...

AXIM - AXIM® Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)'s for Diagnostic Testing of Dry Eye Disease

SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for COVID-19 and cancer, announc...

AXIM - AXIM completes pre-clinical studies on SPX-1009 in suppression of melanoma cells

AXIM Biotechnologies ([[AXIM]]) has completed pre-clinical drug studies on its SPX-1009 compound, demonstrating the suppression of malignant metastatic melanoma cells.The company intends to initiate animal studies to demonstrate the ability of SPX-1009 to suppress tumor growth and m...
AXIM - AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on SPX-1009 Compound Proving Suppression of Melanoma Cells

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting onc...

AXIM - AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files for Approval for Use of Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations in Canada and the EU

SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced ...

AXIM - AXIM Biotechnologies Introduces Diagnostics to Measure Immunity Against Emerging SARS-CoV-2 Variants

SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced...
AXIM - AXIM® Biotechnologies' Manufacturing Partner Empowered Diagnostics Files Emergency Use Authorization With FDA for Use of Its Rapid COVID-19 Neutralizing Antibody Test in Whole Blood at Point-of-Care Locations

SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announce...

AXIM - AXIM completes point-of-care trials for ImmunoPass COVID-19 test

AXIM Biotechnologies (AXIM) has completed point-of-care clinical trials on its ImmunoPass rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies.The test aims to help understand COVID-19 immunity, validate vaccine’s effectiveness and estimate how l...

AXIM - AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announce...
Previous 10 Next 10